SLC29A1 and Alzheimer disease: Two recent studies reported that chronic treatment with an orally active, BBB-permeable small ENT1 inhibitor (J4) attenuated impaired cognitive function, inferior neuroplasticity, and elevated neuroinflammation in two AD mouse models (APP/PS1 and THY-Tau22) [46, 144].